PDF4PRO ⚡AMP

Modern search engine that looking for books and documents around the web

Example: marketing

HIGHLIGHTS OF PRESCRIBING INFORMATION …

HIGHLIGHTS OF PRESCRIBING INFORMATION These HIGHLIGHTS do not include all the INFORMATION needed to use Dacogen safely and effectively. See full PRESCRIBING INFORMATION for Dacogen. DACOGEN (decitabine) for INJECTION Initial Approval: 2006 ------------------------RECENT MAJOR CHANGES----------------------------- Dosage and Administration ( ) 03/2010 -------------------------INDICATIONS AND USAGE------------------------------ Dacogen is a nucleoside metabolic inhibitor indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediat

Dacogen is indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and …

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Spam in document Broken preview Other abuse

Transcription of HIGHLIGHTS OF PRESCRIBING INFORMATION …

Related search queries